Ambrosia Biosciences

About Ambrosia Biosciences

Ambrosia Biosciences is a drug discovery company developing orally delivered, small-molecule therapies for obesity and metabolic disorders. The company combines structure-based drug discovery with cryo-EM–enabled structural biology, biophysical binding assays, and AI-powered design to rapidly iterate from hit to IND using integrated U.S.-based biology and chemistry laboratories, a dedicated NMR facility, and advanced computational capabilities. Its pipeline emphasizes GPCR targets with a focus on GLP-1–based approaches, aiming for best-in-class efficacy and tolerability in metabolic diseases. Headquartered in Boulder, Colorado, Ambrosia pursues safe, effective, and affordable small-molecule medicines to address cardiometabolic conditions.